<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35250990</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune-Mediated Cerebellar Ataxia Associated With Neuronal Surface Antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>813926</StartPage>
          <MedlinePgn>813926</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">813926</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.813926</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune-mediated cerebellar ataxias (IMCAs) are common in paraneoplastic cerebellar degeneration (PCD) but rarely occur in patients with neuronal surface antibodies (NSAbs). Although cerebellar ataxias (CAs) associated with anti-NMDAR and anti-CASPR2 have been reported in a few cases, they have never been studied systematically. This study aimed to analyze the characteristics of anti-NSAbs-associated CAs.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective investigation was conducted to identify patients using the keywords <i>IMCAs</i> and <i>NSAbs</i>. We collected the clinical data of 14 patients diagnosed with anti-NSAbs-associated CAs.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age was 33 years (16-66), and the male-to-female ratio was 4:3. Nine were positive for NMDAR-Ab, two for LGI1-Ab, two for CASPR2-Ab, and one for AMPA2R-Ab. CAs were initial symptoms in three patients and presented during the first two months of the disease course (10 days on average) among the rest of the patients. After the immunotherapy, two cases were free from symptoms, and eight cases recovered satisfactorily (10/14, 71.4%). Compared with other causes of IMCAs, anti-NSAbs were more frequently associated with additional extra-cerebellar symptoms (85.7%), mostly seizures (78.6%) and mental abnormalities (64.3%). In the CSF analysis, pleocytosis was detected in ten patients (71.4%) and oligoclonal bands (OB) were observed in nine patients (64.3%). Moreover, compared with PCD and anti-GAD65-Ab-associated CAs, anti-NSAbs-associated CAs showed a better response to immunotherapy.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IMCAs are rare and atypical in autoimmune encephalitis with neuronal surface antibodies. Compared with other forms of IMCAs, more symptoms of encephalopathy, a higher rate of pleocytosis and positive OB in CSF, and positive therapeutic effect were the key features of anti-NSAbs-associated CAs.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Jia, Li, Li, Zhang, Wang, Jiao, Huang, Ye, Liu and Wang.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Mingyu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Dawei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Mengyao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Huifang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiao</LastName>
            <ForeName>Lidong</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Zhaoyang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Neuromodulation, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Epilepsy, Beijing Institute for Brain Disorders, Capital Medical University, Ministry of Science and Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Neuromodulation, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Epilepsy, Beijing Institute for Brain Disorders, Capital Medical University, Ministry of Science and Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Aihua</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Neuromodulation, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Epilepsy, Beijing Institute for Brain Disorders, Capital Medical University, Ministry of Science and Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuping</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Neuromodulation, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Epilepsy, Beijing Institute for Brain Disorders, Capital Medical University, Ministry of Science and Technology, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Sleep and Consciousness Disorders, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002524" MajorTopicYN="Y">Cerebellar Ataxia</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CSF analysis</Keyword>
        <Keyword MajorTopicYN="Y">immune-mediated cerebellar ataxia</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">neuronal surface antibodies</Keyword>
        <Keyword MajorTopicYN="Y">oligoclonal bands</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35250990</ArticleId>
        <ArticleId IdType="pmc">PMC8891139</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.813926</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. . Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated With Ovarian Teratoma. Ann Neurol (2007) 61(1):25–36. doi: 10.1002/ana.21050
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21050</ArticleId>
            <ArticleId IdType="pmc">PMC2430743</ArticleId>
            <ArticleId IdType="pubmed">17262855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. . AMPA Receptor Antibodies in Limbic Encephalitis Alter Synaptic Receptor Location. Ann Neurol (2009) 65(4):424–34. doi: 10.1002/ana.21589
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21589</ArticleId>
            <ArticleId IdType="pmc">PMC2677127</ArticleId>
            <ArticleId IdType="pubmed">19338055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. . Antibodies to Kv1 Potassium Channel-Complex Proteins Leucine-Rich, Glioma Inactivated 1 Protein and Contactin-Associated Protein-2 in Limbic Encephalitis, Morvan's Syndrome and Acquired Neuromyotonia. Brain (2010) 133(9):2734–48. doi: 10.1093/brain/awq213
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awq213</ArticleId>
            <ArticleId IdType="pmc">PMC2929337</ArticleId>
            <ArticleId IdType="pubmed">20663977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. . Investigation of LGI1 as the Antigen in Limbic Encephalitis Previously Attributed to Potassium Channels: A Case Series. Lancet Neurol (2010) 9(8):776–85. doi: 10.1016/S1474-4422(10)70137-X
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(10)70137-X</ArticleId>
            <ArticleId IdType="pmc">PMC3086669</ArticleId>
            <ArticleId IdType="pubmed">20580615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. . Antibodies to the GABA(B) Receptor in Limbic Encephalitis With Seizures: Case Series and Characterisation of the Antigen. Lancet Neurol (2010) 9(1):67–76. doi: 10.1016/S1474-4422(09)70324-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70324-2</ArticleId>
            <ArticleId IdType="pmc">PMC2824142</ArticleId>
            <ArticleId IdType="pubmed">19962348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Titulaer MJ, Höftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, et al. . Overlapping Demyelinating Syndromes and Anti–N-Methyl-D-Aspartate Receptor Encephalitis. Ann Neurol (2014) 75(3):411–28. doi: 10.1002/ana.24117
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24117</ArticleId>
            <ArticleId IdType="pmc">PMC4016175</ArticleId>
            <ArticleId IdType="pubmed">24700511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Becker EB, Zuliani L, Pettingill R, Lang B, Waters P, Dulneva A, et al. . Contactin-Associated Protein-2 Antibodies in Non-Paraneoplastic Cerebellar Ataxia. J Neurol Neurosurg Psychiatry (2012) 83(4):437–40. doi: 10.1136/jnnp-2011-301506
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2011-301506</ArticleId>
            <ArticleId IdType="pmc">PMC3297806</ArticleId>
            <ArticleId IdType="pubmed">22338029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jarius S, Steinmeyer F, Knobel A, Streitberger K, Hotter B, Horn S, et al. . GABAB Receptor Antibodies in Paraneoplastic Cerebellar Ataxia. J Neuroimmunol (2013) 256(1):94–6. doi: 10.1016/j.jneuroim.2012.12.006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2012.12.006</ArticleId>
            <ArticleId IdType="pubmed">23332614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mitoma H, Manto M, Hampe CS. Immune-Mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges. Curr Neuropharmacol (2019) 17(1):33–58. doi: 10.2174/1570159X16666180917105033
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X16666180917105033</ArticleId>
            <ArticleId IdType="pmc">PMC6341499</ArticleId>
            <ArticleId IdType="pubmed">30221603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. . Treatment and Prognostic Factors for Long-Term Outcome in Patients With Anti-NMDA Receptor Encephalitis: An Observational Cohort Study. Lancet Neurol (2013) 12(2):157–65. doi: 10.1016/S1474-4422(12)70310-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(12)70310-1</ArticleId>
            <ArticleId IdType="pmc">PMC3563251</ArticleId>
            <ArticleId IdType="pubmed">23290630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Iizuka T, Kaneko J, Tominaga N, Someko H, Nakamura M, Ishima D, et al. . Association of Progressive Cerebellar Atrophy With Long-Term Outcome in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. JAMA Neurol (2016) 73(6):706–13. doi: 10.1001/jamaneurol.2016.0232
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2016.0232</ArticleId>
            <ArticleId IdType="pmc">PMC5018902</ArticleId>
            <ArticleId IdType="pubmed">27111481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boyko M, Au KLK, Casault C, de Robles P, Pfeffer G. Systematic Review of the Clinical Spectrum of CASPR2 Antibody Syndrome. J Neurol (2020) 267(4):1137–46. doi: 10.1007/s00415-019-09686-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-019-09686-2</ArticleId>
            <ArticleId IdType="pubmed">31912210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. . A Clinical Approach to Diagnosis of Autoimmune Encephalitis. Lancet Neurol (2016) 15(4):391–404. doi: 10.1016/S1474-4422(15)00401-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00401-9</ArticleId>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gu Y, Zhong M, He L, Li W, Huang Y, Liu J, et al. . Epidemiology of Antibody-Positive Autoimmune Encephalitis in Southwest China: A Multicenter Study. Front Immunol (2019) 10:2611. doi: 10.3389/fimmu.2019.02611
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02611</ArticleId>
            <ArticleId IdType="pmc">PMC6861323</ArticleId>
            <ArticleId IdType="pubmed">31781111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hadjivassiliou M. Immune-Mediated Acquired Ataxias. Handb Clin Neurol (2012) 103:189–99. doi: 10.1016/B978-0-444-51892-7.00011-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-444-51892-7.00011-5</ArticleId>
            <ArticleId IdType="pubmed">21827889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. . Recommended Diagnostic Criteria for Paraneoplastic Neurological Syndromes. J Neurol Neurosurg Psychiatry (2004) 75(8):1135–40. doi: 10.1136/jnnp.2003.034447
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jarius S, Wildemann B. 'Medusa-Head Ataxia': The Expanding Spectrum of Purkinje Cell Antibodies in Autoimmune Cerebellar Ataxia. Part 1: Anti-Mglur1, Anti-Homer-3, Anti-Sj/ITPR1 and Anti-CARP VIII. J Neuroinflamm (2015) 12:166. doi: 10.1186/s12974-015-0356-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0356-y</ArticleId>
            <ArticleId IdType="pmc">PMC4574226</ArticleId>
            <ArticleId IdType="pubmed">26377085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jarius S, Wildemann B. 'Medusa Head Ataxia': The Expanding Spectrum of Purkinje Cell Antibodies in Autoimmune Cerebellar Ataxia. Part 3: Anti-Yo/CDR2, Anti-Nb/AP3B2, PCA-2, Anti-Tr/DNER, Other Antibodies, Diagnostic Pitfalls, Summary and Outlook. J Neuroinflamm (2015) 12:168. doi: 10.1186/s12974-015-0358-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0358-9</ArticleId>
            <ArticleId IdType="pmc">PMC4573944</ArticleId>
            <ArticleId IdType="pubmed">26377319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mitoma H, Adhikari K, Aeschlimann D, Chattopadhyay P, Hadjivassiliou M, Hampe CS, et al. . Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias. Cerebellum (2016) 15(2):213–32. doi: 10.1007/s12311-015-0664-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-015-0664-x</ArticleId>
            <ArticleId IdType="pmc">PMC4591117</ArticleId>
            <ArticleId IdType="pubmed">25823827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for Treatment of Immune-Mediated Cerebellar Ataxias. Cerebellum Ataxias (2015) 2:14. doi: 10.1186/s40673-015-0034-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40673-015-0034-y</ArticleId>
            <ArticleId IdType="pmc">PMC4641375</ArticleId>
            <ArticleId IdType="pubmed">26561527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jia Y, Li M, Wang H, Zhang M, Wang Y. The Peculiar Clinical Symptoms and Treatment of Limbic Encephalitis Associated With AMPA Receptor Antibody. Eur Neurol (2021) 84(3):206–11. doi: 10.1159/000515592
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000515592</ArticleId>
            <ArticleId IdType="pubmed">33857949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Poorthuis MHF, van Rooij JLM, Koch AH, Verdonkschot AEM, Leembruggen MM, Titulaer MJ. Cerebellar Ataxia as a Presenting Symptom in a Patient With Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm (2019) 6(4):e579. doi: 10.1212/NXI.0000000000000579
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000579</ArticleId>
            <ArticleId IdType="pmc">PMC6624087</ArticleId>
            <ArticleId IdType="pubmed">31355315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsunaga A, Ikawa M, Fujii A, Nakamoto Y, Kuriyama M, Yoneda M. Hashimoto's Encephalopathy as a Treatable Adult-Onset Cerebellar Ataxia Mimicking Spinocerebellar Degeneration. Eur Neurol (2013) 69:14–20. doi: 10.1159/000342217
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000342217</ArticleId>
            <ArticleId IdType="pubmed">23128836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nakagawa H, Yoneda M, Fujii A, Kinomoto K, Kuriyama M. Hashimoto's Encephalopathy Presenting With Progressive Cerebellar Ataxia. J Neurol Neurosurg Psychiatry (2007) 78:196–7. doi: 10.1136/jnnp.2006.093005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.093005</ArticleId>
            <ArticleId IdType="pmc">PMC2077662</ArticleId>
            <ArticleId IdType="pubmed">17229749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. . Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies. Lancet Neurol (2008) 7(12):1091–8. doi: 10.1016/S1474-4422(08)70224-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70224-2</ArticleId>
            <ArticleId IdType="pmc">PMC2607118</ArticleId>
            <ArticleId IdType="pubmed">18851928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang J, Qiu Z, Li D, Dong H, Hao J, Liu Z. Anti-Contactin-Associated Protein-Like 2 Antibody-Associated Cerebellar Ataxia: A Case Report and Literature Review. J Neuroimmunol (2021) 353:577515. doi: 10.1016/j.jneuroim.2021.577515
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2021.577515</ArticleId>
            <ArticleId IdType="pubmed">33640718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-Specific Killer Cells in Paraneoplastic Cerebellar Degeneration. Nat Med (1998) 4(11):1321–4. doi: 10.1038/3315
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/3315</ArticleId>
            <ArticleId IdType="pubmed">9809559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Storstein A, Krossnes BK, Vedeler CA. Morphological and Immunohistochemical Characterization of Paraneoplastic Cerebellar Degeneration Associated With Yo Antibodies. Acta Neurol Scand (2009) 120(1):64–7. doi: 10.1111/j.1600-0404.2008.01138.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2008.01138.x</ArticleId>
            <ArticleId IdType="pubmed">19486326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Llansola M, Sanchez-Perez A, Cauli O, Felipo V. Modulation of NMDA Receptors in the Cerebellum. 1. Properties of the NMDA Receptor That Modulate Its Function. Cerebellum (2005) 4(3):154–61. doi: 10.1080/14734220510007996
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14734220510007996</ArticleId>
            <ArticleId IdType="pubmed">16147947</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
